REG - Redx Pharma plc - Share Purchase by a Director

Redx PharmaAnnouncement

12/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240412:nRSL3562Ka&default-theme=true

RNS Number : 3562K  Redx Pharma plc  12 April 2024

REDX PHARMA PLC

("Redx" or the "Company")

Share Purchase by a Director

Alderley Park, UK, 12 April 2024 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, targeted therapeutics for the treatment of fibrotic disease and
cancer today announces that it has been notified that Lisa Anson, Chief
Executive Officer, has on Thursday 11 April 2024 acquired 399,000 Redx
ordinary shares at a price of 7.5 pence per share.  Following this, Lisa
Anson will hold 562,183 ordinary shares in the Company, representing 0.14 per
cent. of the issued share capital.

Further information on the purchase is contained within the disclosure tables
below.

 For further information, please contact:

 Redx Pharma Plc                                                     T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 SPARK Advisory Partners (Nominated Adviser)                         T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 Panmure Gordon (UK) Limited (Broker)                                T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                      T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to clinical
proof of concept before evaluating options for further development and
potential value creation. The Company expects a number of data points during
2024 including from lead fibrosis product candidate, the selective ROCK2
inhibitor, zelasudil (RXC007), in development for interstitial lung disease
and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis
(IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1
development and is expected to report healthy volunteer data; and Redx's lead
oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004),
being developed as a targeted treatment for Wnt-ligand dependent cancers, is
expected to report anti-PD-1 combination Phase 2 data, following which Redx
will seek a partner for ongoing development.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its wholly-owned clinical-stage
product candidates and discovery pipeline, but also by its strategic
transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the
only non-covalent or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please
visit: www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/) .

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.    Details of the person discharging managerial responsibilities (PDMR) / person
       closely associated
 a)    Name                                                           Lisa Anson

 2.    Reason for the notification
 a)    Position / status                                              Chief Executive Officer

 b)    Initial notification / Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                           Redx Pharma plc

 b)    LEI                                                            213800HMS4EBXO589Y37

 4     Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument    Ordinary Shares of 1 pence each in Redx Pharma plc

       Identification code                                            ISIN for Redx Pharma plc Ordinary Shares:

                                                                      GB00BSNB6S51

 b)    Nature of the transaction                                      Purchase of Ordinary Shares
 c)    Prices(a) and volume(s)

Purchase Price per Ordinary Share    Volume
                                                                      7.5 pence                            399,000 Ordinary Shares

 

 d)    Aggregated information

       - Aggregated volume                                            399,000

       - Price                                                        7.5p
 e)    Date of the transaction                                        11 April 2024
 f)    Place of the transaction                                       London Stock Exchange, AIM Market (XLON)

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

399,000

7.5p

e)

Date of the transaction

11 April 2024

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSFIFAFELSEIL